SCHEMBL1706253

SCHEMBL1706253

O=C(O)c1ccc(O)c(OC2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 4/20 0.56
USP2 O75604 4/20 0.56
KDM4E B2RXH2 4/20 0.56
HPGD P15428 4/20 0.56
CASP1 P29466 4/20 0.56
CASP7 P55210 4/20 0.56
HSD17B10 Q99714 4/20 0.56
HKDC1 Q2TB90 3/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
GLA P06280 3/20 0.56
TNNI3 P19429 2/20 0.56
TNNT2 P45379 2/20 0.56
TNNC1 P63316 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
LMNA P02545 1/20 0.56
CYP3A4 P08684 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17653968 0.90 PPARG (0.59) SLC28A3USP2KDM4EHPGDCASP1
Pungenin SCHEMBL29613656 0.89 SLC28A3 (0.65) SLC28A3KDM4EHPGDCASP1CASP7
SCHEMBL5181436 0.87 USP2 (0.57) SLC28A3USP2KDM4EHPGDCASP1
SCHEMBL722959 0.87 USP2 (0.57) SLC28A3USP2KDM4EHPGDCASP1
SCHEMBL4375057 0.87 USP2 (0.57) SLC28A3USP2KDM4EHPGDCASP1
SCHEMBL29711107 0.86 SLC28A3 (0.56) SLC28A3KDM4EHPGDCASP1CASP7
SCHEMBL13576873 0.86 USP2 (0.60) SLC28A3USP2KDM4EHPGDCASP1
SCHEMBL5181812 0.86 USP2 (0.60) SLC28A3USP2KDM4EHPGDCASP1
SCHEMBL13577086 0.86 USP2 (0.60) SLC28A3USP2KDM4EHPGDCASP1
SCHEMBL3232003 0.86 USP2 (0.60) SLC28A3USP2KDM4EHPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4062774-B1 COMPOSITION AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING INCREASED PHENYLALANINE AND REDUCED TOBACCO-SPECIFIC NITROSAMINES (TSNAS) ALTRIA CLIENT SERVICES LLC (US) 2024-03-20 EP disclosed
US-20230348925-A1 COMPOSITION AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING REDUCED TOBACCO-SPECIFIC NITROSAMINES (TSNAS) ALTRIA CLIENT SERVICES LLC (US) 2023-11-02 US disclosed
US-20230109671-A9 Composition and Methods for Producing Tobacco Plants and Products Having Reduced Tobacco-Specific Nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC 2023-04-06 US disclosed
EP-4062774-A1 COMPOSITION AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING INCREASED PHENYLALANINE AND REDUCED TOBACCO-SPECIFIC NITROSAMINES (TSNAS) Altria Client Services LLC (US) 2022-09-28 EP disclosed
EP-3773017-B1 COMPOSITION AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING INCREASED PHENYLALANINE AND REDUCED TOBACCO-SPECIFIC NITROSAMINES (TSNAS) ALTRIA CLIENT SERVICES LLC (US) 2022-06-08 EP disclosed
US-10647989-B2 Composition and methods for producing tobacco plants and products having reduced tobacco-specific nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC (US) 2020-05-12 US disclosed
US-20180119163-A1 Composition and Methods for Producing Tobacco Plants and Products Having Reduced Tobacco-Specific Nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC 2018-05-03 US disclosed
US-9895341-B2 Inflammation and immunity treatments OCEAN SPRAY CRANBERRIES, INC. (US) 2018-02-20 US disclosed
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US disclosed
US-20140134206-A1 INFLAMMATION AND IMMUNITY TREATMENTS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-05-15 US disclosed
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2014-03-27 US disclosed
WO-2012135702-A1 INFLAMMATION AND IMMUNITY TREATMENTS OCEAN SPRAY CRANBERRIES, INC. (US) 2012-10-04 WO disclosed
EP-2027279-B1 Phenolic compounds with cosmetic and therapeutic applications LIBRAGEN (FR) 2012-04-18 EP disclosed
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives LIBRAGEN (FR) 2009-09-17 US disclosed
EP-1867729-A1 Water soluble phenolics derivatives with dermocosmetic and therapeutic applications Libragen (FR) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives UGGT1, TYR, LCT SLC28A3 2244/4885USP2 2372/4885KDM4E 1025/4885
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES UGGT1, TYR, G6PD SLC28A3 2443/4885USP2 2241/4885KDM4E 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.